SCHEMBL7553404

SCHEMBL7553404

c1ccc(C(CC2=NCCN2)c2ccncc2)cc1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 9/20 0.87
MAOA P21397 6/20 0.65
MAOB P27338 6/20 0.65
SLC6A3 Q01959 3/20 0.54
SLC6A2 P23975 2/20 0.54
SLC6A4 P31645 2/20 0.54
TAAR1 Q96RJ0 4/20 0.51
LMNA P02545 2/20 0.51
CYP1A2 P05177 2/20 0.51
ADRA2A P08913 2/20 0.51
CYP2D6 P10635 2/20 0.51
TSHR P16473 2/20 0.51
ADRA2C P18825 2/20 0.51
ADRA1A P35348 2/20 0.51
ADRA2B P18089 1/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1B P35368 1/20 0.51
HTR1A P08908 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
PDE6A P16499 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7547171 0.93 NISCH (1.00) NISCHMAOAMAOBSLC6A3TAAR1
SCHEMBL7548077 0.84 NISCH (0.82) NISCHMAOAMAOBSLC6A3TAAR1
SCHEMBL7548070 0.84 NISCH (0.82) NISCHMAOAMAOBTAAR1LMNA
SCHEMBL7551706 0.83 NISCH (0.81) NISCHMAOAMAOBSLC6A3SLC6A2
SCHEMBL7550070 0.83 NISCH (0.60) NISCHMAOAMAOBSLC6A2SLC6A4
SCHEMBL7551252 0.83 NISCH (0.60) NISCHMAOAMAOBSLC6A3SLC6A2
SCHEMBL7547022 0.83 NISCH (0.60) NISCHMAOAMAOBSLC6A3SLC6A2
SCHEMBL11554305 0.82 NISCH (0.78) NISCHMAOAMAOBSLC6A3SLC6A2
Hydrochloric Acid SCHEMBL11550188 0.82 NISCH (0.78) NISCHMAOAMAOBTAAR1LMNA
SCHEMBL7550483 0.81 NISCH (0.75) NISCHMAOAMAOBTAAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US claimed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO claimed
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed
US-4136188-A TREATMENT OF DIABETES WITH 2-SUBSTITUTED-1,3-DIAZACYCLIC COMPOUNDS DAIICHI SEIYAKU CO., LTD. (JP) 1979-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 NISCH 448/4885MAOA 3214/4885MAOB 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.